Education
About Us
Working with TipRanks
Follow Us
TriSalus Life Sciences (TLSI)
NASDAQ:TLSI
Earnings Data
Report Date
May 14, 2026Before Open (Confirmed)
Period Ending
2026 (Q1)Consensus EPS Forecast
-0.15Last Year’s EPS
-0.39Same Quarter Last Year
Strong Buy
Based on 4 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
The call emphasized strong commercial momentum and sizable top-line growth (Q4 revenue +60% YoY; FY revenue +53%), improved quarterly profitability metrics (higher gross margin and much smaller adjusted EBITDA loss), successful product launches and an oversubscribed $46M financing to fund an aggressive commercial and clinical expansion. Notable negatives include a delayed nelitolimod data release (rescheduled to H2 2026), earlier-year manufacturing inefficiencies that modestly pressured full-year gross margin, higher one-time G&A charges, a worse GAAP loss per share due to capital structure changes, and near-term execution/timing risk as the company ramps its enlarged sales organization. Overall, the positive commercial and financing developments and improving operating performance outweigh the timing and one-time challenges, supporting a favorable outlook while acknowledging execution risk tied to the expansion and product clearance timing.Company Guidance
Strong Top-Line Growth
Q4 revenue of $13.2M, up 60% year-over-year (from $8.3M); Full year revenue of $45.2M, up 53% year-over-year. Company achieved its 2025 revenue growth guidance.
Improved Profitability Metrics in Q4
Q4 gross margin improved to 87% from 85% prior-year period; Q4 net operating loss narrowed to $3.3M from $7.6M; adjusted EBITDA loss improved to approximately $0.95M versus a $5.7M loss in prior-year quarter.
Year-over-Year Operating Leverage
Full-year operating loss decreased to $26.9M from $36.2M a year earlier, driven by higher revenue and margin contribution; gross profit increased by $12.9M year-over-year.
Capital Raise and Balance Sheet Strengthening
Completed an oversubscribed public offering in February raising $46M in gross proceeds (more than 2x oversubscribed) and added veteran healthcare investor Michael Stansky to the Board, improving financial flexibility to fund commercial expansion and clinical programs.
Commercial Portfolio Expansion and Product Launches
Expanded product portfolio from 2 core offerings at the start of 2025 to an expected 7 differentiated offerings in 2026; launched TriNav LV, TriGuide, TriNav FLX and TriNav XP (Q4). TriNav Advance is awaiting 510(k) clearance and anticipated initial launch in H1 2026 with broader rollout in H2 2026.
Market Opportunity and Reimbursement Wins
Reported addressable markets: liver embolization TAM ≈ $480M and broader embolization TAM ≈ $2.3B. CMS introduced HCPCS code C8004 expanding reimbursement for mapping/simulation procedures, effectively doubling reimbursable use in the radio embolization market.
Positive Clinical/Registry Early Data
PROTECT registry preliminary thyroid results: 100% technical and clinical success, no neurovascular complications, 73% reduction in thyroid size, normalization of thyroid function in 71% of participants, and transient mild discomfort in 81% (resolved within two weeks). Initiated pilot GAE registry and preparing GAE clinical trial registry.
Focused Cost and R&D Discipline
R&D spending decreased (Q4 R&D $2.6M vs ~$3.0M prior-year quarter; full-year R&D down ~$2.7M) as PERIO clinical studies were completed and internal nelitolimod development spending was substantially reduced to preserve capital.
TLSI Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
TLSI Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Mar 05, 2026 | $4.77 | $4.46 | -6.39% |
Nov 13, 2025 | $4.39 | $4.56 | +3.87% |
Aug 12, 2025 | $3.65 | $3.95 | +8.22% |
May 15, 2025 | $4.90 | $5.11 | +4.29% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does TriSalus Life Sciences (TLSI) report earnings?
TriSalus Life Sciences (TLSI) is schdueled to report earning on May 14, 2026, Before Open (Confirmed).
What is TriSalus Life Sciences (TLSI) earnings time?
TriSalus Life Sciences (TLSI) earnings time is at May 14, 2026, Before Open (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is TLSI EPS forecast?
TLSI EPS forecast for the fiscal quarter 2026 (Q1) is -0.15.